Table 3.
Lymph node involvement and extrathyroidal extension | 1999 | 2005 | 2008 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Screening | Clinical | Unknown | Screening | Clinical | Unknown | Screening | Clinical | Unknown | ||||
No lymph node involvement: | ||||||||||||
Minimal extension | 0.09 (0.05 to 0.12) | 0.44 (0.36 to 0.52) | 0.38 (0.30 to 0.45) | 1.76 (1.62 to 1.90) | 1.31 (1.19 to 1.43) | 0.75 (0.66 to 0.84) | 5.53 (5.30 to 5.77) | 2.18 (2.03 to 2.33) | 1.56 (1.43 to 1.69) | |||
Gross extension | 0.01 (0.00 to 0.02) | 0.03 (0.01 to 0.05) | 0.01 (0.00 to 0.01) | 0.11 (0.08 to 0.15) | 0.10 (0.07 to 0.13) | 0.00 (0.00 to 0.00) | 0.05 (0.03 to 0.08) | 0.02 (0.01 to 0.04) | 0.02 (0.01 to 0.04) | |||
Subtotal† | 0.10 (0.06 to 0.13) | 0.47 (0.39 to 0.55) | 0.38 (0.31 to 0.45) | 1.87 (1.73 to 2.01) | 1.41 (1.28 to 1.53) | 0.75 (0.66 to 0.84) | 5.59 (5.35 to 5.82) | 2.20 (2.05 to 2.35) | 1.58 (1.46 to 1.71) | |||
Lymph node involvement: | ||||||||||||
None | 0.13 (0.09 to 0.18) | 0.52 (0.43 to 0.60) | 0.16 (0.11 to 0.20) | 1.33 (1.21 to 1.45) | 0.89 (0.79 to 0.99) | 0.46 (0.39 to 0.53) | 3.05 (2.87 to 3.23) | 1.14 (1.02 to 1.25) | 0.89 (0.80 to 0.99) | |||
Minimal extension | 0.13 (0.09 to 0.17) | 0.53 (0.44 to 0.61) | 0.49 (0.41 to 0.57) | 1.43 (1.30 to 1.55) | 1.46 (1.33 to 1.59) | 0.77 (0.68 to 0.86) | 5.48 (5.24 to 5.72) | 2.06 (1.91 to 2.21) | 2.00 (1.86 to 2.15) | |||
Gross extension | 0.01 (0.00 to 0.02) | 0.05 (0.03 to 0.08) | 0.01 (0.00 to 0.02) | 0.12 (0.08 to 0.15) | 0.14 (0.10 to 0.19) | 0.03 (0.01 to 0.05) | 0.04 (0.02 to 0.05) | 0.11 (0.08 to 0.15) | 0.02 (0.00 to 0.03) | |||
Subtotal‡ | 0.27 (0.21 to 0.33) | 1.10 (0.98 to 1.22) | 0.66 (0.57 to 0.75) | 2.87 (2.70 to 3.05) | 2.49 (2.32 to 2.66) | 1.26 (1.14 to 1.38) | 8.56 (8.27 to 8.86) | 3.31 (3.12 to 3.50) | 2.91 (2.74 to 3.09) | |||
Total | 0.37 (0.32 to 0.42) | 1.57 (1.46 to 1.68) | 1.04 (0.95 to 1.13) | 4.74 (4.57 to 4.91) | 3.90 (3.74 to 4.06) | 2.01 (1.89 to 2.12) | 14.15 (13.86 to 14.44) | 5.51 (5.33 to 5.70) | 4.50 (4.33 to 4.66) |
*Calculated per 100 000 population. Segi’s world standard population was used for age standardisation.
†Represents age standardised incidence of regional stage thyroid cancer without regional lymph node involvement.
‡Represents age standardised incidence of regional stage thyroid cancer that involves regional lymph node.